The Anti-Aging Secret Hidden in Your Fat Cells — Dr Mikhail Kolonin
Fat tissue is not the enemy — it is an endocrine organ that protects us from diabetes, and how it ages matters more than how much of it we carry. Dr Mikhail Kolonin describes how GLP-1 medications appear to switch visceral fat toward a heat-burning, brown-like state, using interleukin-6 as an unexpected messenger. His lab also finds telomerase (TERT) rising in the same tissue, linking cellular aging to metabolic activity.
Overview
Dr Mikhail Kolonin opens with the two ways GLP-1 medications reduce body fat: the well-accepted route of reduced appetite and caloric restriction, and a second mechanism his lab has documented — the conversion of white, lipid-storing adipocytes into brown, lipid-burning ones. He then reframes fat tissue itself, explaining that people without enough of it become severely diabetic because lipids spill over into muscle, liver and pancreas.
The key distinction is location: subcutaneous fat is comparatively protective, while visceral fat around the organs tends to expand with age, with cells growing larger, poorly oxygenated and prone to dying. Dying adipocytes recruit immune cells, which release cytokines and set off chronic inflammation that eventually turns systemic. Strikingly, GLP-1s appear to act most strongly on exactly this visceral compartment, activating AMPK and triggering browning in a depot that normally does not brown.
Kolonin then traces the discovery that interleukin-6 — usually cast as a villain — spikes briefly after GLP-1 treatment and acts as the messenger that reaches fat cells, which carry no GLP-1 receptor of their own. Alongside IL-6, his group observes telomerase rising in the same patients, and describes work showing telomerase supports mitochondria, not only telomeres. Without it, in their mouse models, browning does not happen at all.
Key quotes
5Fat is generally viewed as bad for many wrong reasons. It should be viewed as good. We really need fat. Without fat we become very diabetic.
It starts in fat tissue and then it becomes systemic, and that really sets the stage for type 2 diabetes development.
Adipocytes do not express the GLP-1 receptor, so GLP-1 drugs cannot signal to them directly. But IL-6 is the messenger.
We can be healthy with lots of fat tissue as long as our adipocytes are small.
Without TERT, there is no browning, there is no brown fat.
Key ideas
9GLP-1s work through two channels, not one
Reduced appetite and caloric restriction mobilise lipids and shrink adipocytes — the mechanism everyone agrees on. Kolonin's lab has documented a second: activation of a thermogenic program that converts storage cells into heat-producing ones.
Brown fat is modest in humans but still useful
Brown adipose tissue is far more active in rodents than in people, so its contribution to staying warm is limited in humans. It remains relevant because brown fat clears glucose from the bloodstream efficiently.
Too little fat is its own metabolic problem
Lipodystrophy — a genuine lack of fat tissue — pushes the body toward diabetes. Animals with fat tissue genetically removed develop some of the most severe diabetes seen in any model.
Fat tissue is a buffer and an endocrine organ
Its main job is to store surplus energy so that lipids do not spill into muscle, liver and pancreas, where they drive insulin resistance. It also secretes leptin, which signals fullness to the brain, and adiponectin, which supports metabolism.
Visceral fat takes over with age
Body fat shifts from the subcutaneous compartment toward the visceral depot around the organs as we get older. Apple-shaped accumulation tracks with metabolic syndrome, while pear-shaped distribution around the upper legs is comparatively benign.
Enlarged cells, poor oxygen, then inflammation
Visceral adipocytes tend to grow larger with age, become poorly oxygenated and start dying. Immune cells move in, macrophages release cytokines including IL-6, and low-grade inflammation becomes chronic and then systemic.
GLP-1s hit the compartment that matters most
In Kolonin's experiments, AMPK activation and browning appeared far more strongly in visceral than in subcutaneous fat. This is unusual, since cold exposure — the classic browning trigger — acts mainly on fat just under the skin.
IL-6 is a double-edged molecule, not simply a villain
Interleukin-6 is notorious in cancer, senescence and chronic inflammatory disease, and several approved drugs block it. Kolonin's data suggest that a brief, well-placed pulse of IL-6 does something entirely different from sustained elevation.
Telomerase does more than lengthen telomeres
In endothelial cells lacking telomerase, telomeres stayed intact but metabolism shifted from mitochondrial respiration toward inefficient glycolysis — a pattern typical of aging. Telomerase appears to travel to mitochondria and support their number and function.
Practical takeaways
7- 1
Stop treating fat as the enemy 5:10
The goal is healthy fat tissue, not minimal fat tissue. Framing body composition around metabolic function rather than a number on the scale reflects the biology far better.
- 2
Where fat sits tells you more than how much there is 8:00
Waist circumference and the apple-versus-pear pattern carry more metabolic information than total body weight. Tracking waist over time is a simple, free habit.
- 3
Chronic inflammation is the connecting thread 9:40
The route from excess visceral fat to metabolic disease runs through inflammation. Anything that keeps visceral fat in check is also working on inflammation.
- 4
Cold exposure and GLP-1s reach different fat depots 13:20
Cold browns fat near the skin surface; GLP-1 medication appears to brown internal fat. They are complementary levers rather than interchangeable ones.
- 5
Expect person-to-person variation 21:00
Some people show the IL-6 response and strong metabolic activation, others show little. Individual results with these medications differ for reasons researchers are still mapping.
- 6
Small cells, well oxygenated, is the healthier pattern 23:30
People with many small adipocytes stay metabolically healthier than those with fewer, larger ones — one reason younger bodies tolerate higher fat mass better.
- 7
Treat gene-therapy claims with caution 26:00
TERT gene delivery has been reported anecdotally in individuals, but the gene has multiple isoforms and cancers frequently exploit it. This is early research territory, not a protocol.
Topics & chapters
15Two mechanisms behind GLP-1 fat loss
Whether the fat loss comes from eating less or from burning more — and why the answer is both.
White fat, brown fat and glucose clearance
How storage cells convert into heat-producing ones, and what that means for blood sugar in humans versus rodents.
Why we genuinely need fat tissue
Lipodystrophy, ectopic lipid deposition and the diabetes that follows when fat has nowhere to go.
Fat as an endocrine organ
Leptin, adiponectin and the hormonal signals that adipose tissue sends to the rest of the body.
Subcutaneous versus visceral fat
The shift in fat distribution with age, and why apple-shaped accumulation carries the metabolic risk.
How visceral fat drives inflammation
Enlarged, poorly oxygenated cells die, immune cells arrive, and chronic inflammation spreads from tissue to system.
GLP-1s act strongest on visceral fat
AMPK activation and browning showed up preferentially in the internal depot — an unexpected pattern.
Thermogenesis and uncoupling protein 1
Mitochondria that dissipate heat instead of making ATP, and the UCP1 signature unique to brown adipocytes.
Lipolysis with and without thermogenesis
Fatty acids either travel to muscle, liver and brain, or are burned locally inside the fat cell.
The interleukin-6 surprise
A brief IL-6 spike after treatment, and why a molecule with a bad reputation turned out to matter.
IL-6 as the messenger to fat cells
Macrophages carry the GLP-1 receptor, fat cells do not — so IL-6 carries the signal across.
Why responses differ between people
Macrophage numbers, IL-6 activation and the heterogeneity clinicians see with these medications.
Telomerase enters the picture
TERT rising in treated patients alongside glucose uptake, PRDM16 and UCP1.
Telomerase beyond telomeres
Cell size, senescence and the endothelial experiment that pointed toward mitochondria rather than telomere length.
No TERT, no browning — and the caveats
Why telomerase looks essential for thermogenic capacity, and why TERT isoforms make gene-therapy claims complicated.